性早熟GnRH-a治疗后与青春期多囊卵巢综合征发生的相关性

Correlation between idiopathic central precocious puberty treated with GnRH-a and the incidence of polycystic ovarian syndrome

目的探讨特发性中枢性性早熟(ICPP)长效促性腺激素释放激素类似物(GnRH-a)治疗后与青春期多囊卵巢综合征(PCOS)的发生是否具有相关性。方法采用回顾性队列研究,以13至18岁且月经来潮3年以上ICPP女童,其中使用GnRHa治疗者224人为研究组,未治疗者64人为对照组,比较两组间青春期PCOS的发病率。结果研究组女童在随访结束时身高显著高于对照组(t=2.784,P<0.05),而两组年龄、体重、BMI均无显著性差异(t值分别为0.363、0.740、0.863,均P>0.05),随访期间研究组PCOS发病率7.14%,对照组PCOS发病率4.69%,两组无显著性差异(χ2=0.487,P>0.05)。结论使用长效促性腺激素释放激素类似物治疗特发性性早熟未增加青春期多囊卵巢综合征的发生风险。

Objective To explore the correlation between idiopathic central precocious puberty （ICPP） treated with gonadotropin releasing hormone analogs （GnRH-a） and the incidence of polycystic ovarian syndrome （PCOS）. Methods A retrospective cohort study was carried out on girls aged from 13 to 18. All these girls were diagnosed with ICPP and had menses for more than 3 years. Among them, 224 girls were treated with GnRH-a and were recruited in research group. The rest 64 girls who didn＇t undergo GnRH-a treatment were chosen in control group. Incidence rate of pubertal PCOS was compared between two groups. Results The height of girls in the research group at the end of the follow-up was significantly higher than that of the the control group （ t = 2. 784, P 〈 0.05 ）. However, there was no significant difference in age, weight and BMI between two groups （t value was 0. 363, 0. 740 and 0.863, respectively, all P 〉 0.05）. The incidence rate of PCOS in the research group and control group during the follow-up was 7.14% and 4.69%, respectively. No significant difference was identified between two groups （X2 = 0. 487, P 〉 0.05 ）. Conclusions Treating ICPP with GnRH-a does not increase the risk of incidence of PCOS.